Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 176

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study

Newland, Adrian, Godeau, Bertrand, Priego, Victor, Viallard, Jean‐Francois, López Fernández, María F., Orejudos, Amelia, Eisen, Melissa · 2016 · British Journal of Haematology

Abstract

Summary: In anecdotal reports, some patients with immune thrombocytopenia (ITP) maintained platelet counts after discontinuing romiplostim. Here, we examined rates of platelet response (≥50 × 10 9/l), remission, splenectomy and adverse events in patients with primary ITP duration ≤6 months who were treated with romiplostim for ≤12 months. The starting dose of romiplostim was 1 μg/kg; concomitant and rescue treatments were permitted to maintain platelet counts. Patients with platelet counts ≥50 × 10 9/l at the end of 12 months entered a dose taper in which the romiplostim dose was decreased as long as platelet counts were maintained. Remission (platelet count ≥50 × 10 9/l for 24 consecutive weeks with no ITP treatments) was evaluated in patients once romiplostim was discontinued. Over the 12 months, a high response rate (>90%) was observed. Platelet response occurred quickly (median, ~2 weeks) and was observed for a cumulative median of 11 months. Remission was observed in 24 patients (32%); there were no significantly predictors of remission. Most (20/24) patients had remission start before the forced taper. No new safety signals were identified. Thus, in patients with early‐stage ITP, romiplostim was well tolerated and induced rapid responses, with remission occurring in approximately one‐third of patients (NCT 01143038, Amgen 20080435).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjh.13827

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 176

Metadata

Authors
Newland, A., Godeau, B., Priego, V., Viallard, J., López Fernández, M. F., Orejudos, A., & Eisen, M.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2015-11-05
Volume
172
Issue
2
Pages
262-273
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1940859004
Cited by
176
References
1
FWCI
8.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. https://app.cochat.ai/papers/10.1111/bjh.13827
The paper
Newland, A., Godeau, B., Priego, V., Viallard, J., López Fernández, M. F., Orejudos, A., & Eisen, M. (2016). Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. British Journal of Haematology. https://doi.org/10.1111/bjh.13827

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.